Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FREDERICK MIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1366682429
CMS profile
107209
Location
SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,664.34

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,564.39 101
Education $99.95 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FREDERICK MIN

NPI 1366682429 · CMS profile ID 107209

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366682429?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FREDERICK MIN, NPI 1366682429, CMS profile ID 107209. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366682429?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). FREDERICK MIN, NPI 1366682429, CMS profile ID 107209. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366682429?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
FREDERICK MIN, NPI 1366682429, CMS profile ID 107209, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1366682429?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $2,664.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $17.4807/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105693639 CMS
Genentech USA, Inc. $21.5807/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133012579 CMS
AstraZeneca Pharmaceuticals LP $32.2507/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104412477 CMS
Regeneron Healthcare Solutions, Inc. $14.9907/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116001 CMS
GENZYME CORPORATION $21.6307/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139801224 CMS
SHIELD THERAPEUTICS INC $20.1607/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150136969 CMS
Merck Sharp & Dohme LLC $16.6106/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141863683 CMS
ABBVIE INC. $34.1906/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105041417 CMS
AstraZeneca Pharmaceuticals LP $26.7706/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104717647 CMS
AstraZeneca Pharmaceuticals LP $24.0806/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104606450 CMS
Fresenius Kabi USA, LLC $25.6406/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146954804 CMS
Novartis Pharmaceuticals Corporation $21.2406/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086964208 CMS
SOBI, INC $20.6006/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141438357 CMS
Aveo Pharmaceuticals, Inc. $30.5705/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143477541 CMS
Incyte Corporation $99.9505/22/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141298515 CMS
Agios Pharmaceuticals, Inc. $22.9805/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149643604 CMS
ABBVIE INC. $28.5605/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105041415 CMS
Eisai Inc. $21.6205/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110745988 CMS
Ipsen Biopharmaceuticals, Inc $20.6405/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091960272 CMS
Alnylam Pharmaceuticals Inc. $13.2404/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125850555 CMS
Adaptive Biotechnologies Corporation $18.9504/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150262278 CMS
Incyte Corporation $11.6504/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141224222 CMS
Incyte Corporation $11.2504/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141224224 CMS
GlaxoSmithKline, LLC. $34.1404/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116245583 CMS
Incyte Corporation $23.2804/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141315087 CMS
PUMA BIOTECHNOLOGY, INC. $24.0504/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113860419 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.8904/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144963230 CMS
TerSera Therapeutics LLC $28.5704/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144714475 CMS
Incyte Corporation $24.7804/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141224194 CMS
Bayer Healthcare Pharmaceuticals Inc. $30.6904/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086220845 CMS
ARRAY BIOPHARMA INC $17.7204/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131710261 CMS
Novartis Pharmaceuticals Corporation $34.1904/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086964202 CMS
SpringWorks Therapeutics, Inc. $23.2403/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085806447 CMS
BeiGene USA, Inc. $34.8403/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120850648 CMS
Merck Sharp & Dohme LLC $20.3503/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141677453 CMS
Deciphera Pharmaceuticals Inc. $14.0703/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145874259 CMS
Takeda Pharmaceuticals U.S.A., Inc. $27.0103/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144963228 CMS
Alexion Pharmaceuticals, Inc. $33.2002/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094050368 CMS
Mirati Therapeutics, Inc. $24.3802/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117176035 CMS
Novartis Pharmaceuticals Corporation $34.0602/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086964204 CMS
Eisai Inc. $20.0002/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110745990 CMS
Sumitomo Pharma America, Inc. $16.0102/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148891471 CMS
PFIZER INC. $21.4602/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131286670 CMS
Regeneron Healthcare Solutions, Inc. $17.7102/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114115999 CMS
Pharmacosmos Therapeutics Inc. $22.4102/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154824209 CMS
Bayer Healthcare Pharmaceuticals Inc. $29.5502/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086248958 CMS
Janssen Biotech, Inc. $20.7501/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078730358 CMS
TAIHO ONCOLOGY, INC. $19.0001/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137936279 CMS
Daiichi Sankyo Inc. $29.6301/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089457736 CMS
PFIZER INC. $21.9401/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130951909 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $359.96 18
PY2020 $1,235.87 13
PY2021 $765.66 35
PY2022 $1,616.24 71
PY2023 $4,282.19 86
PY2024 $2,664.34 102
PY2025 $2,397.56 99

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,045.72 20
PY2024 Principal investigator $332,041.44 21
PY2023 Principal investigator $223,547.42 25
PY2022 Principal investigator $231,296.70 26
PY2021 Principal investigator $179,224.79 22
PY2020 Principal investigator $21,386.00 2
PY2019 Principal investigator $14,874.78 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genmab U.S., Inc. $5,000.00 11/06/2025 Non-covered Recipient Entity
HOLY CROSS HOSPITAL/CANCER RESEARCH
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer No dispute reported 06/30/2026 1235930616
Principal investigator 1 Daiichi Sankyo Inc. $4,000.00 11/03/2025 Non-covered Recipient Entity
University of Kentucky Medical Center
DS8201-A-U305 No dispute reported 06/30/2026 1244555150
Principal investigator 1 PFIZER INC. $956.00 10/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY PA
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228716299
Principal investigator 1 Hexal AG $1,040.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348690
Principal investigator 1 Hexal AG $1,560.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348694
Principal investigator 1 Hexal AG $2,000.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348696
Principal investigator 1 Hexal AG $208.00 09/11/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348698
Principal investigator 1 Hexal AG $1,081.60 09/01/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348686
Principal investigator 1 AstraZeneca Pharmaceuticals LP $34,728.00 08/06/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer ARTEMIDE-Lung04 No dispute reported 06/30/2026 1185540165
Principal investigator 1 PFIZER INC. $956.00 07/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY PA
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228716117
Principal investigator 1 Daiichi Sankyo Inc. $651.12 06/20/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
DS8201-A-U305 No dispute reported 06/30/2026 1223346970
Principal investigator 1 PFIZER INC. $956.00 04/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY PA
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228716119
Principal investigator 1 AstraZeneca Pharmaceuticals LP $49,905.00 04/09/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 or 20 mutation (DESTINY-Lung04) No dispute reported 06/30/2026 1185540169
Principal investigator 1 AstraZeneca UK Limited $15,540.00 02/17/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY No dispute reported 06/30/2026 1185540163
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,550.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY LAUREL
A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer No dispute reported 06/30/2026 1190307887
Principal investigator 1 PFIZER INC. $956.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY PA
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228716301
Principal investigator 1 AstraZeneca UK Limited $11,098.00 01/08/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
An Open label,Single arm, Phase two,Multinational,Multicentre Study to Assess the Efficacy and Safety of five Years of Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation Positive Stage two 3B Nonsmall Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy TARGET No dispute reported 06/30/2026 1185540167
Principal investigator 1 Hexal AG $780.00 01/03/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348668
Principal investigator 1 Hexal AG $1,040.00 01/03/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348670
Principal investigator 1 Hexal AG $1,040.00 01/03/2025 Covered Recipient Teaching Hospital
Holy Cross Hospital
CGME751A12301 No dispute reported 06/30/2026 1186348802